不同剂量左氧氟沙星治疗利福平耐药肺结核的临床效果

目的:探讨高剂量和低剂量左氧氟沙星治疗利福平耐药肺结核的疗效。方法:选取2019年5月至2020年9月信阳市第五人民医院收治的利福平耐药肺结核患者90例，根据随机数字表法分为高剂量组和低剂量组，各45例。高剂量组男25例、女20例，年龄（42.16±5.05）岁，给予左氧氟沙星0.6 g/d；低剂量组男23例、女22例...

Clinical effects of different doses of levofloxacin in the treatment of rifampicin-resistant pulmonary tuberculosis

Objective　To investigate theclinical effects of different doses of levofloxacin in the treatment ofrifampicin-resistant pulmonary tuberculosis. Methods　A total of 90 patientswith rifampicin-resistant pulmonary tuberculosis were selected from XinyangFifth People's Hospital from May 2019 to September 2020, and were divided intoa high-dose group and a low-dose group according to the random number tablemethod, with 45 cases in each group. In the high-dose group, there were 25males and 20 females, aged (42.16±5.05) years, and they were given levofloxacin0.6 g/d; in the low-dose group, there were 23 males and 22 females, aged(43.27±5.12) years, and they were given levofloxacin 0.4 g/d. The clinicalefficacies, focal absorption rates, quality of life, incidences of adversereactions of the two groups were compared. Independent sample t test was used for the measurementdata, and χ² test was usedfor the count data. Results　The effective rate in the high-dose group [95.56% (43/45)] washigher than that in the low-dose group [75.56% (34/45)], with a statisticallysignificant difference (χ²=7.283, P<0.05). The focal absorption ratein the high-dose group [91.11% (41/45)] was significantly higher than that inthe low-dose group [66.67% (30/45)], with a statistically significantdifference (χ²=8.073, P<0.05). The scores of socialfunction, material life, physical function, and psychological function in thehigh-dose group were (81.25±9.46) points, (81.82±9.39) points, (89.05±8.26)points, and (88.03±9.96) points, which were significantly higher than those inthe low-dose group [(67.34±7.56) points, (64.31±7.42) points, (65.58±7.47)points, and (61.81±7.63) points], with statistically significant differences(all P<0.05). There was nostatistically significant difference in the incidence of adverse reactionsbetween the two groups (χ²=0.080, P=0.777). Conclusion　The clinical effect ofhigh-dose of levofloxacin in the treatment of rifampicin-resistant pulmonarytuberculosis is significant, which can significantly promote the absorption oflesions and improve the patients' quality of life, without increasing adversereactions, with high safety, worthy of further clinical application.